SERUM BUTYRYLCHOLINESTERASE PREDICTS SURVIVAL FOLLOWING EXTRACORPOREAL MEMBRANE OXYGENATION AFTER CARDIOVASCULAR SURGERY  by Goliasch, Georg et al.
Heart Failure and Cardiomyopathies
A858
JACC April 1, 2014
Volume 63, Issue 12
SeruM butyrylcholineSteraSe predictS Survival following extracorporeal MeMbrane 
oxygenation after cardiovaScular Surgery
Poster Contributions
Hall C
Sunday, March 30, 2014, 9:45 a.m.-10:30 a.m.
Session Title: Heart Failure and Cardiomyopathies: Therapy III
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1185-162
Authors: Georg Goliasch, Max-Paul Winter, Kurt Ruetzler, Gottfried Heinz, Irene Lang, Gerald Maurer, Herbert Koinig, Barbara Steinlechner, 
Alexander Niessner, Klaus Distelmaier, Medical University of Vienna, Vienna, Austria
background: Risk stratification in patients undergoing extracorporeal membrane oxygenation (ECMO) support following cardiovascular surgery 
remains challenging, since data on specific outcome predictors are limited. Serum butyrylcholinesterase demonstrated a strong inverse association 
with all-cause and cardiovascular mortality in non-critically ill patients. We therefore evaluated the predictive value of preoperative serum 
butyrylcholinesterase levels in patients undergoing veno-arterial ECMO support following cardiovascular surgery.
Methods: We prospectively included 191 patients undergoing veno-arterial ECMO therapy following cardiovascular surgery at a university-affiliated 
tertiary care center into our registry.
results: All-cause and cardiovascular mortality were defined as primary study endpoints. During a median follow-up time of 51 months (IQR: 34-
71) corresponding to 4197 overall months of follow-up, 65% of patients died. Cox proportional hazard regression analysis revealed a significant 
and independent inverse association between higher butyrylcholinesterase levels and all-cause mortality with an adjusted hazard ratio (HR) of 0.44 
(95%CI 0.25-0.78; p=0.005) as well as cardiovascular mortality with an adjusted HR of 0.38 (95%CI 0.21-0.70; p=0.002) comparing the third with 
the first tertile. Survival rates were higher in patients within the third tertile of butyrylcholinesterase compared to patients within the first tertile at 30 
days (68%vs.44%) as well as at 6 years (47%vs.21%).
conclusions: The current study revealed serum butyrylcholinesterase as a strong and independent inverse predictor of all-cause and 
cardiovascular mortality in patients undergoing veno-arterial ECMO therapy following cardiovascular surgery. These findings advance the limited 
knowledge on risk stratification in patients undergoing ECMO support and represent a valuable addition for a comprehensive decision-making prior 
to ECMO implantation.
